Original BioMedicals , Ltd. Overview
Latest ROE for Original BioMedicals , Ltd.: -171.73% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-171.73%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for 6483.TWO is -171.73%. That is below the sector sector average of 11.73%. Investors often review this figure alongside Original BioMedicals , Ltd.'s historical trend and sector peers before judging valuation or financial health.
Against its sector companies, 6483.TWO currently prints -171.73% for ROE, while the sector average sits near 11.73%. That is roughly 1563.5% below the sector mean. Large gaps often invite a closer look at Original BioMedicals , Ltd.'s growth, margins, and balance sheet.
Return on Equity shows how effectively Original BioMedicals , Ltd. converts resources into returns. At -171.73%, 6483.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 6483.TWO's ROE (-171.73%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
